San Mateo, CA (PRWEB) November 07, 2012
Entelos, a premier provider of in silico modeling and simulation products and consulting services that help pharmaceutical and consumer product companies make better decisions in their product development process, was selected to present new findings on the contribution of vessel size and geometry to rate of plaque formation in humans and mice in a scientific poster at the annual American Heart Association conference this week. The work, performed using Entelos’s computer model of coronary heart disease (CHD), provides a mechanistic rationale for the observed variation in the rate of plaque progression in differently sized human vessels, and those of laboratory mice. The poster will be featured at the American Heart Association (AHA) annual Scientific Sessions November 6-8 in Los Angeles. Entelos will be discussing the topic in a live webinar on November 15, 10AM PDT.
“These simulations demonstrate how in silico models can deliver important mechanistic understandings of disease progression and perform experiments that are difficult or impossible using conventional testing. Specifically, Entelos PhysioLab experiments enable the systematic exploration of individual biological properties and pathways.” said Shawn O’Connor, president and CEO of Entelos. “It further demonstrates that paired quantitative models calibrated to human and animal data provide a methodology for improving translation from pre-clinical to clinical status.”
The Entelos Cardiovascular PhysioLab is a mathematical model of CHD developed for use in target ranking, translation of animal to human efficacy, the identification of new biomarkers, and the prediction of clinical trial outcomes. The Cardiovascular PhysioLab quantitatively simulates the dynamic interactions of lipoproteins (Lp) with cellular and extracellular components of the arterial wall. The model incorporates known drivers of plaque growth including lipoprotein retention, endothelial dysfunction, macrophage recruitment and egress, cellular cholesterol uptake and efflux to HDL and vascular cell death. The AHA poster: Mathematical modeling identifies vessel size and geometry as key factors determining the rate of plaque development in mouse and human can be viewed at http://www.entelos.com/resources/.
To register for the webinar :https://cc.callinfo.com/r/1f3w8ajdzaoo3.
Entelos provides fully developed Physiolab platforms in multiple disease areas in addition to Cardiovascular Disease including: Metabolism (diabetes), Rheumatoid Arthritis, Hypertension (with heart and kidney failure), Dermatology, Hematology, Infection, Nutrition, and Veterinary Nutrition.
Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company’s PhysioLab systems biology platforms generate virtual patient populations providing predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos’ understanding of patient variability has significant application to the emerging field of personalized medicine. The Company is headquartered in San Mateo, California. For more information, please visit http://www.entelos.com.